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Background:  Melanogenesis is one of the characteristic 
parameters of differentiation in melanocytes and melanoma 
cells. Specific inhibitors of phosphatidylinositol 3-kinase 
(PI3K), such as wortmannin and LY294002, stimulate 
melanin production in mouse and in human melanoma cells, 
suggesting that PI3K and mammalian target of rapamycin 
(mTOR) might be involved in the regulation of melano-
genesis. Objective: The involvement of the mTOR pathway 
in regulating melanogenesis was examined using human 
MNT-1 melanoma cells, and the effects of the potent 
inhibitor of mTOR, rapamycin, in the presence or absence of 
α-melanocyte-stimulating hormone (α-MSH) were evaluated. 
Methods: In cells treated with rapamycin, cell viability, 
melanin content, and tyrosinase (TYR) activity were mea-
sured and compared with untreated controls. Protein levels 
of TYR, tyrosinase-related protein (TYRP)-1, TYRP-2, and 
microphthalmia-associated transcription factor (MITF) were 
also analyzed by Western blot. Results: In rapamycin-treated 
cells, the melanin content increased concomitantly with an 
elevation in TYR activity, which plays a major role in 
melanogenesis. There was also an up-regulation of TYR, 
TYRP-1, and MITF proteins. Combined treatment with 
rapamycin or wortmannin and α-MSH increased melano-
genesis more strongly than α-MSH alone. Conclusion: 
Rapamycin-induced melanin formation may be mediated 
through the up-regulation of TYR protein and activity. 
Furthermore, rapamycin and wortmannin, inhibitors of 
mTOR and PI3K, respectively, have co-stimulatory effects 
with α-MSH in enhancing melanogenesis in melanocyte 
cells. (Ann Dermatol 24(2) 151∼157, 2012)
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INTRODUCTION
Melanogenesis is a complex, multistage process involving 
melanin synthesis in melanosomes, the transport of 
melanosomes to the dendrite tips of the melanocytes, and 
their release. In melanocytes and in melanoma cells, 
melanin synthesis is controlled by a cascade of enzymatic 
reactions. The initial step of melanin synthesis begins with 
the oxidation of tyrosine to 3,4-dihydroxyphenylalanine 
(DOPA) by tyrosinase (TYR), the rate-limiting enzyme of 
melanogenesis
1. Melanogenesis is stimulated by various 
effectors, including paracrine melanogenic factors (α- 
melanocyte-stimulating hormone [α-MSH], endothelin-1, 
stem cell factor, basic fibroblast growth factor), cyclic 
adenosine monophosphate (cAMP)-elevating agents (fors-
kolin, isobutylmethylxanthine, cholera toxin), and ultra-
violet B radiation
2. Melanogenesis is regulated via various 
intracellular signaling pathways including protein kinases, 
such as protein kinase A (PKA)
3, protein kinase C-α  (PKC-
α)
4, protein kinase C-β (PKC-β)
5, and mitogen-activated YS Hah, et al
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protein kinase (MAPK)
6,7. The cAMP pathway especially 
plays a key role in the regulation of melanogenesis 
through the up-regulation of the key transcription factor  
microphthalmia-associated transcription factor and sub-
sequent melanogenic enzymes including pre-existing TYR 
protein and TYR mRNA
3,8,9. 
Mammalian target of rapamycin (mTOR) is a serine-threonine 
kinase involved in a number of important cellular pro-
cesses such as cell growth and proliferation, cell motility, 
cellular metabolism, and autophagy
10,11. mTOR exists 
within mammalian cells in two functionally and struc-
turally distinct forms of a multi-protein complex, mTORC1 
and mTORC2, which take charge of different sets of 
signaling pathways
12. mTORC1 is composed of mTOR, 
GβL, and raptor, and is rapamycin-sensitive. However, 
mTORC2, which consists of mTOR, GβL, mSIN1, PRR5, 
and rictor, is not responsive to rapamycin. mTORC1 can 
be activated by various stimuli through different upstream 
molecules in which growth factors affect mTOR via the 
phophoinositol-3-kinase (PI3K)/Akt pathway
13. PI3K initiates 
a cascade that ultimately results in the activation of Akt. 
Akt then inhibits the activity of tuberous sclerosis complex 
2, which then activates mTOR signaling. S6K1 and 
4E-BP1, downstream effectors of mTOR, regulate the 
translation of specific mRNAs including MITF. Recently, 
Ohguchi et al.
14 reported a negative regulatory role for 
phospholipase D1 (PLD1) in the melanogenic process 
through the mTOR/S6K1 pathway in B16 melanoma cells. 
Furthermore, recent studies have shown that specific 
inhibitors of PI3K, such as wortmannin and LY294002, 
stimulate melanin production in mouse and in human 
melanoma cells, suggesting that the PI3K pathway might 
be involved in the regulation of melanogenesis
15,16. 
However, direct evidence for the involvement of mTOR in 
the regulation of melanin synthesis has not been eluci-
dated.
In this study, we investigated whether the PI3K/mTOR 
pathway is involved in melanogenesis using human MNT-1 
melanoma cells. For this purpose, we used rapamycin and 
wortmannin, potent inhibitors of mTOR and PI3K, 
respectively. Our results show that rapamycin has a more 
potent stimulating effect on melanogenesis than α-MSH 
or wortmannin. Furthermore, combinations of α-MSH 
with rapamycin or wortmannin show stronger effects on 
melanogenesis than α-MSH alone. The results are 
consistent with the conclusion that melanin synthesis is 
regulated through the PI3K/mTOR pathway, and rapa-
mycin and wortmannin synergize with α-MSH to induce 
melanogenesis.
MATERIALS AND METHODS
Cell culture
MNT-1 cells are highly pigmented human melanoma 
cells, and were acquired as gift from Dr. Vincent Hearing 
(Pigment Cell Biology Section, NIH, USA). These cells 
were cultured in minimal essential medium supplemented 
with 20% (v/v) heat-inactivated fetal bovine serum, 10% 
AIM-V medium, 20 mM HEPES, streptomycin-penicillin 
(100 μg/ml each), 0.1 mM nonessential amino acids, and 
1 mM sodium pyruvate at 37
oC in a humidified 
atmosphere of 5% CO2 in air. Monolayers of confluent 
MNT-1 cells were harvested with a mixture of 0.05% 
trypsin and 0.53 mM EDTA (Gibco BRL, Grand Island, 
NY, USA).
Cell viability assay
Cell viability was detected using a CellTiter non-radioactive 
assay kit (Promega, Madison, WI, USA) and estimated by 
measuring the metabolism of 3-(4, 5-dimethyldiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT). Briefly, 300 μl 
MTT solution (5 mg/ml) was added to each well of a 
24-well plate, and cells were maintained for 1 hour at 
37
oC. Then, 100 μl solubilization solution (50% dimethyl-
formamide and 20% sodium dodecyl sulfate [SDS], pH 
4.8) were added to each well. Absorbance was measured 
at 570 nm, with a microplate reader. Cell viability was 
expressed as a percentage of cytoprotection versus con-
trols set at 100%.  
Measurement of melanin content
Cells were seeded in 6-well plates (Becton Dickinson, 
Franklin Lakes, NJ, USA) at a density of 1×10
5 cells per 
well and were allowed to attach overnight. The cells were 
then incubated in fresh medium containing various 
concentrations of rapamycin, dissolved in dimethylsulfoxide  
at a final concentration of 0.1% v/v. For determination of 
melanin content, the MNT-1 cells were washed with 
phosphate-buffered saline (PBS) and dissolved in 250 μl 
of 1 N NaOH for 1 hour at 80
oC and transferred to 96- 
well plates. The melanin contents were determined by 
measuring absorbance at a wavelength of 405 nm.
TYR activity
TYR activity was determined as described previously
17 
with slight modifications. Briefly, MNT-1 cells were 
cultured in six-well plates. After incubation with rapa-
mycin for 3 days, the cells were washed in ice-cold PBS 
and were lysed with phosphate buffer (pH 6.8) containing 
1% Triton X-100 and protease inhibitors (Complete
TM 
protease inhibitor mixture; Roche Molecular Diagnostics, Induction of Melanogenesis by Rapamycin
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Fig. 1. Effects of rapamycin on melanin content and the proliferation of MNT-1 cells. MNT-1 cells were treated with various 
concentrations of rapamycin for 48 hours. (A) Melanin content. (B) Cell viability determined by the metabolism of 3-(4, 
5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Melanin content and cell proliferation are expressed as percentage of 
the control. Data represent means±standard deviation of at least three independent experiments. Significant differences were determined 
by Student’s t-test; *p＜0.01, **p＜0.001 versus control.
Mannheim, Germany). The lysates were clarified by 
centrifugation for 10 minutes at 10,000 g. After the quan-
tifying protein levels and adjusting concentrations using 
lysis buffer, 90 μl of each lysate, containing an identical 
amount of protein, were placed in 96-well plates, and 10 
μl 15 mM L-DOPA was added to each well. After 
incubation at 37
oC for 30 minutes, dopachrome formation 
was assayed by measuring absorbance at 475 nm using a 
microplate reader. TYR activity is reported as percentage 
values.
Western blot analysis
Cells were lysed in cold lysis buffer (0.1 M Tris-HCl, pH 
7.2, 1% Nonidet P-40, 0.01% SDS, 1 mM phenylmethyl-
sulfonyl fluoride, 10 μg/ml leupeptin, 1 μg/ml aprotinin) 
and were centrifuged at 15,000 g for 15 minutes. Total 
protein contents in the supernatants were measured using 
a BCA protein assay kit (Pierce, Rockford, IL, USA). Thirty 
micrograms of protein were resolved by 8% SDS-polyacrylamide 
gel electrophoresis and were electrophoretically transferred 
to nitrocellulose membranes, using the semidry 
technique. After blocking for 1 hour with 5% skim milk in 
TBS-T buffer solution (10 mM Tris, 150 mM NaCl, and 
0.1% Tween-20), each membrane was incubated with 
primary antibody against TYR, tyrosinase-related protein 
(TYRP)-1, TYRP-2, MITF, and β-actin (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Specific antibody 
binding was detected using horseradish peroxidase- 
conjugated secondary antibody (Santa Cruz Biotechnology), 
and was visualized by enhanced chemiluminescence 
detection (Pierce). The amount of protein (arbitrary unit) 
was quantified using an imaging densitometer and 
expressed as averages of triplicate experiments.
Statistical analysis
Each experiment was performed at least three times, with 
results expressed in each case as the mean±standard 
deviation (SD). Significant differences between results 
were determined by Student’s t-test. p-values of ＜0.05 
were taken to be significant.
RESULTS
Effects of rapamycin on melanin content and MNT-1 
cell proliferation
MNT-1 cells were treated with various concentrations of 
rapamycin for 48 hours. Melanogenesis was then deter-
mined by measuring intracellular melanin contents, which 
are shown as percentage values. Cell proliferation was 
also expressed as a percentage relative to the control. The 
effects of rapamycin on melanin content and the prolife-
ration of MNT-1 cells are shown in Fig. 1. Rapamycin 
showed a melanogenesis-enhancing effect in a concentration- 
dependent manner (Fig. 1A), but had no significant effect 
on cell proliferation (Fig. 1B).
Effects of rapamycin on TYR activity in MNT-1 cells
To elucidate the mechanism by which rapamycin 
stimulates melanogenesis, MNT-1 cells were treated with 
rapamycin at a concentration of 100 nM. Melanogenesis 
is regulated by the activity of TYR, the rate limiting 
enzyme in melanin biosynthesis. Thus, we examined the YS Hah, et al
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Fig. 2. Effects of rapamycin on Tyrosinase (TYR) activity in MNT-1 cells. MNT-1 cells were treated with rapamycin (100 nM) or α-
melanocyte-stimulating hormone (α-MSH) (100 nM) for the indicated times. (A) Melanin content. (B) TYR activity determined by
measuring the formation of dopachrome. Melanin content and TYR activity are expressed as percentage of the control. Data are expressed
as means±standard deviation of at least three independent experiments. *p＜0.01, **p＜0.001 versus control.
effect of rapamycin on TYR activity. After rapamycin 
treatment, melanin contents were significantly increased 
in a time-dependent manner (Fig. 2A). As shown in Fig. 
2B, TYR activity was also increased during the 24∼48 
hours after the addition of 100 nM rapamycin. According 
to these results, we hypothesized that the rapamycin- 
induced melanin formation is mediated via the activation 
of TYR activity.
Effects of rapamycin on TYR, TYRP-1, TYRP-2, and 
MITF expression in MNT-1 cells
In order to further clarify the mechanism of rapamycin- 
induced melanogenesis, protein levels of TYR, TYRP-1, 
TYRP-2, and MITF in MNT-1 cells were determined by 
Western blot analysis. As shown in Fig. 3A and B, levels 
of TYR, TYRP-1, and MITF were significantly enhanced 
after rapamycin treatment in a time-dependent manner 
compared to the control, whereas there was no effect of 
rapamycin on TYRP-2 levels. After treatment with 100 nM 
α-MSH, the protein levels of TYR and TYRP-1 were 
slightly increased in a time-dependent fashion. These 
results suggest that rapamycin-induced melanin formation 
can be mediated via up-regulated levels of TYR, TYRP-1, 
and MITF proteins.
Stimulatory effects of the combination of α-MSH and 
rapamycin or wortmannin on melanogenesis
To determine the potential stimulatory effects of rapa-
mycin and wortmannin, specific inhibitors of mTOR and 
PI3K, respectively, on α-MSH-induced melanogenesis, 
the cells were treated with α-MSH (100 nM) and/or 
rapamycin (100 nM) and/or wortmannin (1 μM) for 72 
hours. When rapamycin or wortmannin were simulta-
neously added with α-MSH, melanin synthesis increased 
dramatically (Fig. 4) in terms of pellet color (Fig. 4A) and 
melanin content (Fig. 4B). The combination of α-MSH 
and rapamycin especially showed the most potent 
enhancing effect on melanin production, eliciting a 3.7- 
fold increase compared to the 2-fold increase elicited by 
rapamycin treatment alone. 
DISCUSSION
Cell-permeable inhibitors of PI3K/mTOR, such as wort-
mannin and rapamycin, are potent tools for dissecting 
intracellular signaling networks. Wortmannin inhibits 
several protein kinases structurally related to PI3K
18 and 
DNA-dependent protein kinase
19, whereas other protein 
kinases, such as PKA, PKC, and cyclic guanosine mono-
phosphate-dependent protein kinase, are insensitive to 
wortmannin at concentrations up to 1 μM
20. Rapamycin 
is a potent inhibitor of mTOR which is implicated in 
regulating cell growth and proliferation
12,16.
Melanogenesis is one of the major functions of pigmented 
cells such as normal melanocytes and malignant mela-
noma cells. In this study, we demonstrate that the PI3K/ 
mTOR pathway is involved in regulating melanin syn-
thesis, and that α-MSH has a co-stimulatory effect on 
melanogenesis with inhibitors of this pathway in highly 
pigmented human MNT-1 melanoma cells. In rapamycin- 
treated cells, the intracellular melanin content increased in 
dose-dependent  (Fig. 1A) and time-dependent (Fig. 2A) Induction of Melanogenesis by Rapamycin
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Fig. 3. Effects of rapamycin on expression of Tyrosinase (TYR), TYRP-1, TYRP-2 and MITF proteins. (A) MNT-1 cells were treated 
with various concentrations of rapamycin (10, 100, 1,000 nM) and α-melanocyte-stimulating hormone (100 nM) as noted for the 
indicated times. Cells were then subjected to Western blot analysis performed using antibodies against TYR, TYRP-1, TYRP-2 and 
MITF. Equal protein loadings were confirmed using an anti-actin antibody. (B) The amount of protein (arbitrary unit) was quantified 
using an imaging densitometer. The results are averages of triplicate experiments, and the data are expressed as mean±standard 
deviation. Rm: Rapamycin, MSH: α-melanocyte-stimulating hormone, TYRP: tyrosinase-related protein, MITF: microphthalmia-associated
transcription factor.YS Hah, et al
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Fig. 4. Effects on melanin production. MNT-1 cells were stimulated with 100 nM rapamycin (Rm) and/or 1 μM wortmannin (Wm)
and/or 100 nM α-melanocyte-stimulating hormone (MSH) for 72 hours. (A) Macroscopic view of cell pellets. (B) After the incubation
period, melanin contents were measured and are expressed as percentage of the untreated control (mean±standard deviation). *p＜0.05,
**p＜0.001 versus control.
manners. We compared the effects of rapamycin with 
those of α-MSH, a positive control in those trials because 
of its known stimulatory effects on melanin synthesis
21. 
Our results show that the stimulatory effect of rapamycin 
on melanin production in MNT-1 cells was stronger than 
that of α-MSH (Fig. 2A). To elucidate the mechanism of 
action of rapamycin on melanogenesis, we measured the 
enzyme activity of TYR. TYR activity increased signifi-
cantly at 24∼48 hours after the addition of 100 nM 
rapamycin (Fig. 2B). This enhancing effect of rapamycin 
was more potent than α-MSH, suggesting that the in-
creased melanogenesis elicited by rapamycin could be 
achieved, at least in part, by its stimulatory action on the 
signaling pathways responsible for the regulation of TYR.
TYR mRNA levels are generally correlated with TYR 
activity
22. In our study, rapamycin treatment increased the 
protein levels of MITF, a transcription factor implicated in 
the regulation of TYR gene expression and melanogenic 
enzymes such as TYR, TYRP-1, and TYRP-2 (Fig. 3), 
indicating that MITF up-regulates the expression of TYR 
and TYRP-1 mRNAs in rapamycin-treated cells. In other 
words, the rapamycin-induced stimulation of melano-
genesis is achieved by the transcriptional regulation of 
those melanogenic enzymes.
Melanin synthesis in pigment cells is regulated by a 
complex and interconnected set of intracellular signaling 
pathways, including PKA (stimulated by cAMP elevators
23), 
PKC (stimulated by endothelins), and MAPK (ERK1 and 
ERK2; stimulated by growth factors
6,7). The cAMP pathway 
plays a pivotal role in the regulation of melanogenesis 
through the activation of PKA and cAMP responsive 
element binding protein (CREB), which leads to up- 
regulation of the expression of MITF
3. Among the signaling 
pathways putatively involved in melanocyte activation, 
the PI3K/mTOR pathway seems to be a good candidate for 
studies of pigmentation, since PI3K has been implicated in 
the differentiation of dendritic neuronal cells
24 and PLD1, 
an upstream activator of mTOR, exerts a negative regula-
tory role on melanogenesis through the mTOR pathway in 
B16 melanoma cells
16. Taken together, it is clear that 
melanogenesis is regulated by a network of several 
signaling mechanisms including the mTOR pathway. But 
the precise mechanisms connecting the PI3K/mTOR path-
way with melanogenesis have not yet been elucidated. 
This study demonstrates that the inhibition of mTOR leads 
to a stimulation of melanin synthesis that correlates well 
with increased TYR activity and the protein levels of TYR 
and MITF. Meanwhile, similar effects were observed with 
wortmannin, indicating that inhibition of the PI3K/mTOR 
pathway plays an important role in regulating melanin 
synthesis. However, wortmannin was markedly less effec-
tive in stimulating melanin production than was rapa-
mycin (Fig. 4A). Interestingly, analysis of melanin contents 
revealed that the combination of α-MSH and rapamycin 
have a potent co-stimulation of melanin synthesis (Fig. 
4B). One possible explanation of this is that the α- 
MSH-associated cAMP pathway promotes the activation of 
PKA and CREB, with the inhibition of the mTOR pathway 
by rapamycin increasing the expression of MITF, thereby 
simultaneously leading to the induction of melanogenic 
enzymes such as TYR and TYRP-1.
In summary, we demonstrate that rapamycin, an inhibitor 
of mTOR, is a positive regulator of melanogenesis in terms 
of melanin content, TYR activity, and protein levels of Induction of Melanogenesis by Rapamycin
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melanogenic enzymes as well as MITF. We further show 
that rapamycin and wortmannin synergize with α-MSH in 
stimulating melanin synthesis through the inhibition of 
mTOR and PI3K, respectively. The PI3K/mTOR pathway is 
involved in regulating melanin production through the 
regulation of MITF expression. This study performed in 
melanoma cells has a limitation in terms of pigment cell 
types. Studies done using normal human melanocytes or 
in vivo models will be better and more physiologically 
relevant.
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